Please use this identifier to cite or link to this item:
https://doi.org/10.3390/cancers12061705
Title: | Potential of tyrosine kinase receptor TIE-1 as novel therapeutic target in high-PI3K-expressing ovarian cancer | Authors: | Zhang, X. Ishibashi, M. Kitatani, K. Shigeta, S. Tokunaga, H. Toyoshima, M. Shimada, M. Yaegashi, N. |
Keywords: | Molecular targeted therapy Ovarian cancer PI3K TIE-1 |
Issue Date: | 2020 | Publisher: | MDPI AG | Citation: | Zhang, X., Ishibashi, M., Kitatani, K., Shigeta, S., Tokunaga, H., Toyoshima, M., Shimada, M., Yaegashi, N. (2020). Potential of tyrosine kinase receptor TIE-1 as novel therapeutic target in high-PI3K-expressing ovarian cancer. Cancers 12 (6) : 1-14. ScholarBank@NUS Repository. https://doi.org/10.3390/cancers12061705 | Rights: | Attribution 4.0 International | Abstract: | Tyrosine kinase receptor TIE-1 plays a critical role in angiogenesis and blood-vessel stability. In recent years, increased TIE-1 expression has been observed in many types of cancers; however, the biological significance and underlying mechanisms remain unknown. Thus, in the present study, we investigated the tumor biological functions of TIE-1 in ovarian cancer. The treatment of SKOV3 ovarian-cancer cells with siRNA against TIE-1 decreased the expression of key molecules in the PI3K/Akt signaling pathway, such as p110? and phospho-Akt, suggesting that TIE-1 is related to the PI3K/Akt pathway. Furthermore, the knockdown of TIE-1 significantly decreased cell proliferation in high-PI3K-expressing cell lines (SKOV3, CAOV3) but not low-PI3K-expressing cell lines (TOV112D, A2780). These results suggested that inhibition of TIE-1 decreases cell growth in high-PI3K-expressing cells. Moreover, in low-PI3K-expressing TOV112D ovarian-cancer cells, TIE-1 overexpression induced PI3K upregulation and promoted a PI3K-mediated cell proliferative phenotype. Mechanistically, TIE-1 participates in cell growth and proliferation by regulating the PI3K/Akt signaling pathway. Taken together, our findings strongly implicate TIE-1 as a novel therapeutic target in high-PI3K-expressing ovarian-cancer cells. � 2020 by the authors. Licensee MDPI, Basel, Switzerland. | Source Title: | Cancers | URI: | https://scholarbank.nus.edu.sg/handle/10635/197727 | ISSN: | 20726694 | DOI: | 10.3390/cancers12061705 | Rights: | Attribution 4.0 International |
Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_3390_cancers12061705.pdf | 2.6 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License